| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 629.6 | 545.4 | 601.3 |
| Other income | 10.3 | 12.8 | 11.3 |
| Total income | 639.9 | 558.2 | 612.6 |
| Profit before exceptional items & tax | 223.7 | 113.1 | 181.1 |
| Profit before tax | 223.7 | 113.1 | 181.1 |
| Net profit | 165.9 | 84.5 | 129.3 |
| Operating margin | 35.0% | 20.3% | 29.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +28.30% |
|---|---|
| Net profit, quarter on quarter | +96.30% |
| Revenue, year on year | +4.70% |
| Operating profit, year on year | +31.90% |
| Operating profit, quarter on quarter | +117.00% |
BSE results filing, NSE: LALPATHLAB. Figures extracted from the filing.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹1,952.30
- Market cap
- ₹32,769 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 60.5×Sector 57.8×
- Promoter holding
- 53.19%-0.02% QoQ
- FII holding
- 17.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Acquisition Worth ₹38 Cr
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
- Value
- ₹38.00 Cr
Dr. Lal Pathlabs Acquisition
Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.
Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs will hold a board meeting on November 04, 2026, to consider and approve standalone and consolidated financial results for the quarter ending September 30, 2026.
Dr. Lal Pathlabs Employee Stock Options
Designated persons and the company's Employee Welfare Trust disclosed multiple equity transactions, including ESOP exercises and market sales, in a recent regulatory filing.
- Value
- ₹1.42 Cr
Dr. Lal Pathlabs Acquisition Worth ₹168 Cr
Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.
- Value
- ₹168.0 Cr
Dr. Lal Pathlabs Acquisition Worth ₹199.5 Cr
Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.
- Value
- ₹199.5 Cr